WO2022155792A1 - Hydrogel à base d'alginate de sodium chargé de lutéine, son procédé de préparation et son utilisation - Google Patents
Hydrogel à base d'alginate de sodium chargé de lutéine, son procédé de préparation et son utilisation Download PDFInfo
- Publication number
- WO2022155792A1 WO2022155792A1 PCT/CN2021/072739 CN2021072739W WO2022155792A1 WO 2022155792 A1 WO2022155792 A1 WO 2022155792A1 CN 2021072739 W CN2021072739 W CN 2021072739W WO 2022155792 A1 WO2022155792 A1 WO 2022155792A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lutein
- sodium alginate
- protein isolate
- solution
- chickpea protein
- Prior art date
Links
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 title claims abstract description 174
- 239000001656 lutein Substances 0.000 title claims abstract description 171
- 229960005375 lutein Drugs 0.000 title claims abstract description 171
- 235000012680 lutein Nutrition 0.000 title claims abstract description 170
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 title claims abstract description 170
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 title claims abstract description 170
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 title claims abstract description 170
- 239000000017 hydrogel Substances 0.000 title claims abstract description 103
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 239000000661 sodium alginate Substances 0.000 title claims abstract description 80
- 235000010413 sodium alginate Nutrition 0.000 title claims abstract description 80
- 229940005550 sodium alginate Drugs 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 235000019705 chickpea protein Nutrition 0.000 claims abstract description 78
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims abstract description 23
- 229960003681 gluconolactone Drugs 0.000 claims abstract description 23
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 23
- 230000000968 intestinal effect Effects 0.000 claims abstract description 19
- 238000011068 loading method Methods 0.000 claims abstract description 17
- 238000005538 encapsulation Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 78
- 239000002105 nanoparticle Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 238000001879 gelation Methods 0.000 claims description 7
- 239000008055 phosphate buffer solution Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 26
- 238000010521 absorption reaction Methods 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 23
- 210000001072 colon Anatomy 0.000 description 21
- 108010074328 Interferon-gamma Proteins 0.000 description 19
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical group C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 18
- 102100037850 Interferon gamma Human genes 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 102000004889 Interleukin-6 Human genes 0.000 description 15
- 229940100601 interleukin-6 Drugs 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000000018 Chemokine CCL2 Human genes 0.000 description 10
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 9
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 9
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 8
- 241000692845 Rikenellaceae Species 0.000 description 7
- 229920003045 dextran sodium sulfate Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- -1 small molecule compound Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 108090000600 Claudin-1 Proteins 0.000 description 4
- 241001425580 Deferribacteraceae Species 0.000 description 4
- 241001467894 Desulfovibrionaceae Species 0.000 description 4
- 101710142059 Free fatty acid receptor 2 Proteins 0.000 description 4
- 101710142057 Free fatty acid receptor 3 Proteins 0.000 description 4
- 241000095588 Ruminococcaceae Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000606126 Bacteroidaceae Species 0.000 description 3
- 102000004162 Claudin-1 Human genes 0.000 description 3
- 241000609971 Erysipelotrichaceae Species 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 description 3
- 102100040136 Free fatty acid receptor 3 Human genes 0.000 description 3
- 108090000304 Occludin Proteins 0.000 description 3
- 241000192142 Proteobacteria Species 0.000 description 3
- 108010002321 Tight Junction Proteins Proteins 0.000 description 3
- 241001261005 Verrucomicrobia Species 0.000 description 3
- 241001183271 Verrucomicrobiaceae Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 241000605059 Bacteroidetes Species 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241001248432 Helicobacteraceae Species 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 241001112693 Lachnospiraceae Species 0.000 description 2
- 102000012064 NLR Proteins Human genes 0.000 description 2
- 108091005686 NOD-like receptors Proteins 0.000 description 2
- 102000003940 Occludin Human genes 0.000 description 2
- 241000692844 Prevotellaceae Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102000000591 Tight Junction Proteins Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 241001568341 Bdellovibrionaceae Species 0.000 description 1
- 241001430332 Bifidobacteriaceae Species 0.000 description 1
- 241000372691 Candidatus Saccharibacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 244000045195 Cicer arietinum Species 0.000 description 1
- 241001657523 Coriobacteriaceae Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 241001143296 Deferribacteres <phylum> Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241000692843 Porphyromonadaceae Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000813827 Sutterellaceae Species 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000006047 digesta Substances 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
Definitions
- Figure 9 shows the comparison diagram of the content of inflammatory factor interleukin-6 (IL-6) in the serum of mice with different treatments in the present invention
- Figure 11 shows a graph showing the comparison of the expression levels of the gene TNF- ⁇ in the colon tissue of mice by different treatments in the present invention
- Figure 26 shows the family-level distribution characteristics of the intestinal flora of mice with different treatments of the present invention.
- the absorption peak at 1025cm-1 represents the stretching vibration of C-O, and this characteristic peak is the absorption peak shared by polysaccharides, which is closely related to galacturonic acid and paleo in AH Llucuronic acid related.
- the broad absorption peak at 3246 cm-1 represents the asymmetric stretching vibration of -OH in the polysaccharide.
- the absorption peaks at 1593 cm-1 and 1404 cm-1 represent the symmetric and asymmetric stretching vibrations of AH's characteristic COO-, respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un hydrogel à base d'alginate de sodium chargé de lutéine, son procédé de préparation et son utilisation. L'hydrogel à base d'alginate de sodium chargé en lutéine comprend les ingrédients suivants en parties en poids : 3,12 à 10,53 parties en poids de lutéine, 46,8 à 47,7 parties en poids d'un isolat de protéines de pois chiches, 120 à 125 parties en poids d'alginate de sodium, 8,4 à 42 parties en poids de Ca2+-EGTA, et 7,12 à 35,6 parties en poids de D-gluconolactone. L'invention concerne en outre un procédé de préparation de l'hydrogel à base d'alginate de sodium chargé de lutéine. L'hydrogel à base d'alginate de sodium obtenu chargé de lutéine a une capacité de charge de lutéine de 760 μg/g et une efficacité d'encapsulation de 96 % ou plus, et présente une bonne performance de chargement de médicament et une bonne performance de libération prolongée. L'invention concerne en outre son utilisation dans la préparation d'un médicament pour la prévention ou le traitement de maladies provoquées par des taux de facteurs inflammatoires et des structures microbiennes intestinales.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/072739 WO2022155792A1 (fr) | 2021-01-19 | 2021-01-19 | Hydrogel à base d'alginate de sodium chargé de lutéine, son procédé de préparation et son utilisation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/072739 WO2022155792A1 (fr) | 2021-01-19 | 2021-01-19 | Hydrogel à base d'alginate de sodium chargé de lutéine, son procédé de préparation et son utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022155792A1 true WO2022155792A1 (fr) | 2022-07-28 |
Family
ID=82548157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2021/072739 WO2022155792A1 (fr) | 2021-01-19 | 2021-01-19 | Hydrogel à base d'alginate de sodium chargé de lutéine, son procédé de préparation et son utilisation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022155792A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116210897A (zh) * | 2023-01-18 | 2023-06-06 | 中国海洋大学 | 一种ros响应型虾青素抗炎水凝胶及其制备方法与应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030064133A1 (en) * | 2001-08-23 | 2003-04-03 | Bio-Dar Ltd | Stable coated microcapsules |
| CN107184566A (zh) * | 2017-05-19 | 2017-09-22 | 澳门大学 | 含有叶黄素的药物组合物及其制备方法和制剂 |
| CN109452648A (zh) * | 2018-12-14 | 2019-03-12 | 杨鹏熙 | 叶绿素-海藻酸钠微球的制备方法 |
| US20190254302A1 (en) * | 2018-01-23 | 2019-08-22 | Cornell University | Systems and methods for controlling the release from enzyme-responsive microcapsules with a smart natural shell |
| CN111938157A (zh) * | 2020-08-17 | 2020-11-17 | 江苏省农业科学院 | 一种叶黄素纳米乳液的制备方法 |
-
2021
- 2021-01-19 WO PCT/CN2021/072739 patent/WO2022155792A1/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030064133A1 (en) * | 2001-08-23 | 2003-04-03 | Bio-Dar Ltd | Stable coated microcapsules |
| CN107184566A (zh) * | 2017-05-19 | 2017-09-22 | 澳门大学 | 含有叶黄素的药物组合物及其制备方法和制剂 |
| US20190254302A1 (en) * | 2018-01-23 | 2019-08-22 | Cornell University | Systems and methods for controlling the release from enzyme-responsive microcapsules with a smart natural shell |
| CN109452648A (zh) * | 2018-12-14 | 2019-03-12 | 杨鹏熙 | 叶绿素-海藻酸钠微球的制备方法 |
| CN111938157A (zh) * | 2020-08-17 | 2020-11-17 | 江苏省农业科学院 | 一种叶黄素纳米乳液的制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| HUANG JIN, FEIFEI BAI, YANCHEN WU, QINGZHUO YE, DONG LIANG, CAIHONG SHIC, XIANGRONG ZHANG: "Development and evaluation of lutein-loaded alginate microspheres with improved stability and antioxidant", JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, vol. 99, 29 April 2019 (2019-04-29), XP055953586, DOI: 10.1002/jsfa.9766 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116210897A (zh) * | 2023-01-18 | 2023-06-06 | 中国海洋大学 | 一种ros响应型虾青素抗炎水凝胶及其制备方法与应用 |
| CN116210897B (zh) * | 2023-01-18 | 2024-09-13 | 中国海洋大学 | 一种ros响应型虾青素抗炎水凝胶及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2768499C2 (ru) | Комбинированная пре- и пробиотическая композиция | |
| Xiao et al. | Effects of dietary administering chitosan on growth performance, jejunal morphology, jejunal mucosal sIgA, occluding, claudin-1 and TLR4 expression in weaned piglets challenged by enterotoxigenic Escherichia coli | |
| EP2124972A2 (fr) | Utilisation d'une composition de substances minérales et éventuellement de bactéries acétogènes et/ou butyrogènes pour empêcher ou diminuer la formation de gaz dans le gros intestin d'un mammifère et les douleurs abdominales qui en résultent | |
| JP2015527308A (ja) | プロバイオティクスを封入するための微粒子、この微粒子を得ることおよびその使用 | |
| JP2018531977A (ja) | 免疫機能を調節するため及び腸の炎症を治療するためのベータ−１，３−グルカンの使用 | |
| WO2022155792A1 (fr) | Hydrogel à base d'alginate de sodium chargé de lutéine, son procédé de préparation et son utilisation | |
| WO2017009676A1 (fr) | Compositions de conservation et de reconstitution de symbiose microbiote-hôte | |
| JP2022514351A (ja) | 腸管バリア治癒を促進するための組成物および方法 | |
| KR102568433B1 (ko) | 사이클로덱스트린-커큐민 캡슐화된 키토산/알지네이트 경구용 나노입자 및 이의 대장염 치료 용도 | |
| Feng et al. | Curcumin-loaded high internal phase emulsions alleviated dextran sulfate sodium-induced ulcerative colitis in mice via inhibiting inflammatory response and modulating gut microbiota | |
| KR100871050B1 (ko) | 코엔자임큐텐을 함유한 미세캡슐의 제조방법 | |
| EP3866615B1 (fr) | Complément alimentaire pour le traitement de la dysbiose | |
| JPWO2004009800A1 (ja) | ラクトバシラス・カゼイ亜種カゼイ増殖促進用組成物 | |
| LU102522B1 (en) | Lutein-loaded sodium alginate-based hydrogel, preparation method and application thereof | |
| Ge et al. | Preparation of microgels loaded with lycopene/NMN and their protective mechanism against acute liver injury | |
| Zhang et al. | Exploring pectin-casein micelles as novel carriers for oral drug delivery of artesunate in the treatment of systemic lupus erythematosus | |
| WO2021029322A1 (fr) | Composition pour prévenir ou soulager des maladies liées au mode de vie | |
| TWI837063B (zh) | 結腸靶向之活性劑遞送載體及其用途 | |
| CN114796155B (zh) | 天然活性物质-玉米蛋白纳米颗粒及其制备方法和用途 | |
| CN114848832B (zh) | 一种调控l细胞分泌glp-1的结肠靶向控释递送系统和应用 | |
| US20190307816A1 (en) | Probiotic Formulation and Method for Weight Loss Treatment | |
| CN117247569A (zh) | 卵清蛋白原纤维-白藜芦醇自组装水凝胶的制备方法及其应用 | |
| CN116807994A (zh) | 一种结肠靶向释放脂肪酸的壳聚糖纳米微粒及其制备方法 | |
| Zhu et al. | Inulin‐Based Nanoparticle Modulates Gut Microbiota and Immune Microenvironment for Improving Colorectal Cancer Therapy | |
| CN117297088A (zh) | 一种结肠靶向纳米颗粒及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21920197 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21920197 Country of ref document: EP Kind code of ref document: A1 |